Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia

Haematologica

Volumn 97, Issue 11, 2012, Pages 1704-1707

  Alvarez Larrán, Alberto ^a   Ancochea, Agueda ^a   Angona, Anna ^a   Pedro, Carme ^a   García Pallarols, Francesc ^a   Martínez Avilés, Luz ^a   Bellosillo, Beatriz ^a   Besses, Carlos ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Essential thrombocythemia; Hematocrit; Hemoglobin; Polycythemia vera; Red cell mass

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HEMATOCRIT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROCYTE VOLUME; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; SEX FACTORS; THROMBOCYTOPENIA;

EID: 84868556615     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067348     Document Type: Article

References (17)

1. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol. 2001;38(1 Suppl 2):21-4.
2. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-7
3. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383-7.
4. Cervantes F, Alvarez-Larrán A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786-90.
5. Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Saumell S, Salar A, Abella E, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146 (5):504-9.
6. Berk P, Wasserman LR, Fruchtman SM, Goldberg JT. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In Polycythemia vera and the myeloproliferative disorders. Ed. Wasserman LR, Berk PD, Berlin BI. W. B Saunders company Philadelphia, PA. 1995;166-94.
7. Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116 (8):1205-10.
8. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
9. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-70.
10. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129 (5):701-5.
11. Lamy T, Devillers A, Bernard M, Moisan A, Grulois I, Drenou B, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med. 1997; 102(1):14-20.
12. Cassinat B, Laguillier C, Gardin C, de Beco V, Burcheri S, Fenaux P, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22(2):452-3.
13. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi Gferrant A, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89(4):748-56.
14. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6.
15. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytosis and in primary thrombocythaemia. Br J Haematol. 2002;117(1):47-53.
16. Wetswood NB, Pearson TC. Diagnostic applications of haemopoeietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma. 1996:22(Suppl 1):95-103.
17. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-9.